GUBamy: Dosing Protocols

Investigational Status#

GUBamy (GUB014295) is an early-stage investigational medication with only phase 1 clinical trial data available. All dosing information is derived from phase 1 SAD and MAD study results. Dosing should only occur within the context of authorized clinical trials.

Phase 1 Dosing Data#

Single Ascending Dose (SAD) Study#

The phase 1 SAD study evaluated single subcutaneous doses of GUBamy in healthy volunteers:

• Dose range: Multiple ascending doses up to approximately 6 mg
• Key findings:
  • GUBamy was well tolerated at all doses
  • Dose-proportional pharmacokinetics confirmed
  • Half-life of approximately 270 hours (11 days) confirmed
  • Dose-dependent weight loss: approximately 3% in the three highest dose groups (3.5-6.0 mg) over 6 weeks vs approximately +1% in placebo

Multiple Ascending Dose (MAD) Study -- Interim Results#

The phase 1 MAD study evaluated repeated weekly dosing:

Key observations:

• The 7.77% weight loss at day 43 is exceptionally strong for a phase 1 study
• GI adverse events were predominantly mild, consistent with SAD data
• The 2 mg weekly dose appeared to have a favorable benefit-risk profile

Dose Selection Considerations#

Amylin Analog Class Experience#

Dosing for amylin-class agents typically requires:

1. Gradual dose escalation: To minimize nausea and vomiting (the primary dose-limiting toxicity of amylin agonism)
2. Individual dose titration: Based on GI tolerability and weight loss response
3. Maintenance dosing: Once the target dose is reached and tolerated

Factors That May Influence Dose Selection for Phase 2#

• Efficacy vs tolerability: Higher doses may produce more weight loss but with more GI side effects
• Combination potential: If combined with GLP-1 RAs, lower GUBamy doses may be sufficient
• Long half-life: The 11-day half-life means dose adjustments take 2-3 weeks to reach new steady state

Administration#

Injection Technique (Clinical Trial)#

1. Administer subcutaneously in the abdomen or thigh
2. Rotate injection sites between weekly doses
3. Follow the clinical trial dose escalation schedule
4. Inject on the same day each week

Practical Considerations#

• Once-weekly convenience: 52 injections per year (vs 365 for pramlintide thrice daily)
• Long half-life: Provides consistent drug levels throughout the dosing interval
• Food timing: No specific food timing requirements have been reported (unlike pramlintide, which is taken with meals)

Dosing Context#

GUBamy belongs to the Metabolic category of research peptides. Dosing protocols for GUBamy are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.

Research Protocols#

The following dosing protocols have been documented in clinical research for GUBamy:

Obesity (Phase 1 Clinical Trial Doses)#

Dose: Phase 1 SAD evaluated single doses up to 6 mg. Phase 1 MAD evaluated 2 mg once weekly subcutaneously, with 7.77% weight loss by day 43.

Frequency: Once weekly subcutaneous injection

Duration: Phase 1 MAD evaluated over approximately 6 weeks

Early-stage dosing only. Phase 2 doses may differ. Dose escalation likely required based on GI tolerability, consistent with the amylin analog class.

Protocol Quick Reference#

Primary Use: Obesity (weight management)

Dosing Summary: 2 mg (phase 1 MAD dose showing efficacy) administered Once weekly for Ongoing (6 weeks evaluated in phase 1).

Route of Administration: subcutaneous (Once weekly).

Timing Notes: Weekly subcutaneous injection

Cycle Duration: Ongoing.

Storage: Likely refrigerated (2-8 degrees C). Consult clinical trial protocol.

Additional Considerations#

• Early-stage investigational drug (phase 1 only)
• Only available through clinical trials
• Dose escalation likely required based on class experience
• Phase 2 dosing may differ from phase 1

Reconstitution and Preparation#

Formulation details not publicly disclosed. Administered as a subcutaneous injection in clinical trials.

Injection Sites#

Recommended injection sites for GUBamy include:

• Abdomen
• Thigh

Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.

Storage Requirements#

Storage requirements not publicly disclosed. Likely requires refrigeration based on peptide formulation standards.

Related Reading#

• GUBamy overview and research guide
• GUBamy side effects profile
• GUBamy research evidence